ECSP066455A - Antagonistas del receptor de trombina - Google Patents
Antagonistas del receptor de trombinaInfo
- Publication number
- ECSP066455A ECSP066455A EC2006006455A ECSP066455A ECSP066455A EC SP066455 A ECSP066455 A EC SP066455A EC 2006006455 A EC2006006455 A EC 2006006455A EC SP066455 A ECSP066455 A EC SP066455A EC SP066455 A ECSP066455 A EC SP066455A
- Authority
- EC
- Ecuador
- Prior art keywords
- thrombine
- receiver antagonists
- antagonists
- receiver
- compounds
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000003856 thrombin receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/671,216 US7488742B2 (en) | 2000-06-15 | 2003-09-25 | Thrombin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066455A true ECSP066455A (es) | 2006-09-18 |
Family
ID=34393462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006455A ECSP066455A (es) | 2003-09-25 | 2006-03-24 | Antagonistas del receptor de trombina |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7488742B2 (https=) |
| EP (1) | EP1663965B1 (https=) |
| JP (1) | JP4694490B2 (https=) |
| KR (1) | KR20060128848A (https=) |
| CN (1) | CN101128457A (https=) |
| AR (1) | AR045809A1 (https=) |
| AU (1) | AU2004276327B2 (https=) |
| BR (1) | BRPI0414592A (https=) |
| CA (1) | CA2540163C (https=) |
| CO (1) | CO5680428A2 (https=) |
| EC (1) | ECSP066455A (https=) |
| IL (1) | IL174538A0 (https=) |
| MX (1) | MXPA06003379A (https=) |
| MY (1) | MY143834A (https=) |
| NO (1) | NO20061797L (https=) |
| PE (1) | PE20050471A1 (https=) |
| RU (1) | RU2367660C9 (https=) |
| SG (1) | SG147466A1 (https=) |
| TW (1) | TWI331608B (https=) |
| WO (1) | WO2005030712A2 (https=) |
| ZA (1) | ZA200602448B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| BRPI0309309B8 (pt) * | 2002-04-16 | 2021-05-25 | Merck Sharp & Dohme | antagonistas de receptor de trombina tricíclicos |
| ES2427166T3 (es) * | 2003-06-23 | 2013-10-29 | Ono Pharmaceutical Co., Ltd. | Compuesto heterocíclico tricíclico novedoso |
| CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
| US20060063930A1 (en) * | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
| US8563511B2 (en) * | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| US7488752B2 (en) * | 2004-10-08 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| WO2006068164A1 (ja) * | 2004-12-22 | 2006-06-29 | Ono Pharmaceutical Co., Ltd. | 三環式化合物およびその用途 |
| CA2875768C (en) | 2005-01-14 | 2018-03-06 | George G. Wu | Process for the preparation of phosphonate compounds useful in the preparation of himbacine analogs |
| US7776889B2 (en) * | 2005-03-31 | 2010-08-17 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| JP2009521458A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体 |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| AU2007243657A1 (en) * | 2006-03-29 | 2007-11-08 | Schering Corporation | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| US8003803B2 (en) * | 2006-04-13 | 2011-08-23 | Schering Corporation | Fused ring thrombin receptor antagonists |
| EP2032560B1 (en) * | 2006-06-29 | 2013-05-01 | Merck Sharp & Dohme Corp. | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| EP2069326B1 (en) | 2006-10-04 | 2015-03-18 | Merck Sharp & Dohme Corp. | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| EP2120879A2 (en) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| BRPI0809095A2 (pt) * | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
| SI2242740T1 (sl) | 2008-02-05 | 2013-03-29 | Sanofi | SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila |
| RS52264B (sr) | 2008-02-05 | 2012-10-31 | Sanofi | Triazolopiridazini kao inhibitori par1, njihovo dobijanje i upotreba kao lekova |
| RU2494100C2 (ru) * | 2008-02-05 | 2013-09-27 | Санофи-Авентис | Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства |
| EP2438060B1 (en) | 2009-06-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Active metabolite of a thrombin receptor antagonist |
| JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
| ES2532902T3 (es) | 2010-04-16 | 2015-04-01 | Sanofi | Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1 |
| WO2011128420A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| WO2015013083A1 (en) | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
| WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| EP3035928B1 (en) * | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| EP3035929B1 (en) * | 2013-08-22 | 2024-07-03 | Merck Sharp & Dohme LLC | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| WO2016114386A1 (ja) * | 2015-01-15 | 2016-07-21 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患治療剤 |
| CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法 |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| CZ298578B6 (cs) * | 1997-11-25 | 2007-11-14 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující |
| AU6690001A (en) | 2000-06-15 | 2001-12-24 | Schering Corp | Thrombin receptor antagonists |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| KR100960170B1 (ko) * | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
| BRPI0309309B8 (pt) * | 2002-04-16 | 2021-05-25 | Merck Sharp & Dohme | antagonistas de receptor de trombina tricíclicos |
| CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
| JP2008526254A (ja) * | 2005-01-14 | 2008-07-24 | シェーリング コーポレイション | ヒンバシン類似物のキラルプロパルギルアルコールおよびエステル中間体の調製 |
| CA2875768C (en) * | 2005-01-14 | 2018-03-06 | George G. Wu | Process for the preparation of phosphonate compounds useful in the preparation of himbacine analogs |
| US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
| WO2006076452A2 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | An exo-selective synthesis of himbacine analogs |
-
2003
- 2003-09-25 US US10/671,216 patent/US7488742B2/en not_active Expired - Lifetime
-
2004
- 2004-09-23 CN CNA2004800278261A patent/CN101128457A/zh active Pending
- 2004-09-23 SG SG200807889-1A patent/SG147466A1/en unknown
- 2004-09-23 AU AU2004276327A patent/AU2004276327B2/en not_active Ceased
- 2004-09-23 MX MXPA06003379A patent/MXPA06003379A/es active IP Right Grant
- 2004-09-23 TW TW093128874A patent/TWI331608B/zh not_active IP Right Cessation
- 2004-09-23 AR ARP040103439A patent/AR045809A1/es unknown
- 2004-09-23 RU RU2006113638/04A patent/RU2367660C9/ru not_active IP Right Cessation
- 2004-09-23 WO PCT/US2004/031495 patent/WO2005030712A2/en not_active Ceased
- 2004-09-23 CA CA2540163A patent/CA2540163C/en not_active Expired - Fee Related
- 2004-09-23 EP EP04789042.1A patent/EP1663965B1/en not_active Expired - Lifetime
- 2004-09-23 PE PE2004000927A patent/PE20050471A1/es not_active Application Discontinuation
- 2004-09-23 JP JP2006528258A patent/JP4694490B2/ja not_active Expired - Fee Related
- 2004-09-23 KR KR1020067005753A patent/KR20060128848A/ko not_active Ceased
- 2004-09-23 BR BRPI0414592-5A patent/BRPI0414592A/pt not_active IP Right Cessation
- 2004-09-24 MY MYPI20043931A patent/MY143834A/en unknown
-
2006
- 2006-03-23 IL IL174538A patent/IL174538A0/en unknown
- 2006-03-23 CO CO06029040A patent/CO5680428A2/es not_active Application Discontinuation
- 2006-03-24 ZA ZA200602448A patent/ZA200602448B/en unknown
- 2006-03-24 EC EC2006006455A patent/ECSP066455A/es unknown
- 2006-04-24 NO NO20061797A patent/NO20061797L/no not_active Application Discontinuation
-
2008
- 2008-10-30 US US12/261,514 patent/US20090076088A1/en not_active Abandoned
- 2008-10-30 US US12/261,545 patent/US20090069383A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090069383A1 (en) | 2009-03-12 |
| CN101128457A (zh) | 2008-02-20 |
| EP1663965B1 (en) | 2014-04-09 |
| US20040152736A1 (en) | 2004-08-05 |
| MY143834A (en) | 2011-07-15 |
| WO2005030712A8 (en) | 2007-12-21 |
| CA2540163C (en) | 2012-06-05 |
| CO5680428A2 (es) | 2006-09-29 |
| WO2005030712A2 (en) | 2005-04-07 |
| RU2367660C9 (ru) | 2010-08-10 |
| ZA200602448B (en) | 2007-09-26 |
| AU2004276327B2 (en) | 2010-10-07 |
| CA2540163A1 (en) | 2005-04-07 |
| JP2007523051A (ja) | 2007-08-16 |
| JP4694490B2 (ja) | 2011-06-08 |
| TW200524914A (en) | 2005-08-01 |
| TWI331608B (en) | 2010-10-11 |
| MXPA06003379A (es) | 2006-06-08 |
| IL174538A0 (en) | 2006-08-01 |
| RU2367660C2 (ru) | 2009-09-20 |
| US20090076088A1 (en) | 2009-03-19 |
| BRPI0414592A (pt) | 2006-11-07 |
| US7488742B2 (en) | 2009-02-10 |
| KR20060128848A (ko) | 2006-12-14 |
| NO20061797L (no) | 2006-05-19 |
| SG147466A1 (en) | 2008-11-28 |
| EP1663965A2 (en) | 2006-06-07 |
| AU2004276327A1 (en) | 2005-04-07 |
| WO2005030712A3 (en) | 2007-09-20 |
| RU2006113638A (ru) | 2007-11-10 |
| PE20050471A1 (es) | 2005-08-24 |
| AR045809A1 (es) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066455A (es) | Antagonistas del receptor de trombina | |
| UY29267A1 (es) | Derivados de piperidina y su uso como agentes antiinflamatorios | |
| CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
| MX2012005994A (es) | Compuestos de 2-piridona. | |
| ECSP10010724A (es) | Compuestos de isoindol 5-sustituidos | |
| CR9814A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| UY28760A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico | |
| UY28572A1 (es) | Compuestos novedosos | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| DOP2006000193A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| AR045900A1 (es) | Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos. | |
| ES2139959T3 (es) | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. | |
| CR8274A (es) | Piridina, pirazina y pirimidinas fusionados con heteroarilos como receptores de crf1 | |
| UY29176A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. | |
| NI200900040A (es) | Derivados de quinazolinona 5-substituidos como agentes antitumorales. | |
| UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
| NI200900031A (es) | Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. | |
| CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
| UY27851A1 (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| ECSP088270A (es) | Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO6640204A2 (es) | Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapéuticos | |
| UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina |